The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.62

Today's change-0.72 -4.15%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.
 

Boston Scientific Corp

NYSE: BSX
Last

(U.S.) $16.62

Today's change-0.72 -4.15%
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Boston Scientific Corp down (U.S.)$0.72

Boston Scientific Corp closed sharply lower Friday, dropping (U.S.)$0.72 or 4.15% to (U.S.)$16.62. Over the last five days, shares have lost 5.19% and are down 9.87% for the last year to date. This security has outperformed the S&P 500 by 18.69% during the last year.

Key company metrics

  • Open(U.S.) $17.25
  • Previous close(U.S.) $17.34
  • High(U.S.) $17.43
  • Low(U.S.) $16.58
  • Bid / Ask-- / --
  • YTD % change-9.87%
  • Volume17,077,341
  • Average volume (10-day)13,122,026
  • Average volume (1-month)10,683,234
  • Average volume (3-month)10,154,655
  • 52-week range(U.S.) $14.18 to (U.S.) $19.06
  • Beta1.00
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward16.05×
  • Forward PEG1.23×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.18
Updated February 5 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-3.20%

Although this company's net profit margin is negative, it is above the industry average and implies that Boston Scientific Corp is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.08%Sector:HealthcareIndustry:Advanced Medical Equipment
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2015Q3/2015Q2/2015Q1/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015
Revenue1,9781,8881,8431,768
Total other revenue--------
Total revenue1,9781,8881,8431,768
Gross profit1,4161,3541,3111,256
Total cost of revenue562534532512
Total operating expense2,2492,1871,6241,744
Selling / general / administrative772720696660
Research & development244221220192
Depreciation / amortization135131116113
Interest expense (income), net operating--------
Unusual expense (income)51956442250
Other operating expenses, total17171817
Operating income-271-29921924
Interest income (expense), net non-operating-59-58-106-60
Gain (loss) on sale of assets--------
Other--------
Income before tax-338-367105-51
Income after tax-142-198102-1
Income tax, total-196-1693-50
Net income-142-198102-1
Total adjustments to net income--------
Net income before extra. items-142-198102-1
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-142-198102-1
Inc. avail. to common incl. extra. items-142-198102-1
Diluted net income-142-198102-1
Dilution adjustment--------
Diluted weighted average shares1,3461,3441,3621,334
Diluted EPS excluding extraordinary itemsvalue per share-0.11-0.150.070.00
Dividends per sharevalue per share--0.000.000.00
Diluted normalized EPSvalue per share0.150.130.100.12